

Figure 1. (A) Sequencing results from monoallelic clone (MAC) and biallelic clone (BAC) with the arrow indicating place with 13 nucleotide deletion in *HNF1A* gene; (B) Representative pictures of pluripotent markers (OCT4, SSEA-4, NANOG, TRA-1-60) in control 2 and its respective clones; (C) Representative pictures of pluripotent markers of hiPSCs colonies, derived from two *HNF1A*-MODY patients – MODY3a and MODY3b.




Figure 2. (A) Representative pictures showing expression of phospho-eNOS and VE-cadherin (left panel, red-peNOS and green VE-cadherin), von Willebrand Factor (vWF, right panel, green) in HPSI control and *HNF1A* mutated cells (clone 4), in both panels nucleus were stained with DAPI (blue); (B) Representative pictures of HPSI control iPSC-ECs and *HNF1A* heterozygous clones, showing expression of angiopoietin 1 (upper panel, green) and angiopoietin 2 (lower panel, red) together with VE-cadherin; (C) Representative pictures of vWF (green) and phospho-eNOS (red) in control 2 and respective *HNF1A* clones; (D) Representative pictures showing expression of phospho-eNOS (left panel) and angiopoietin 1 (right panel, both in green) together with VE-cadherin (red).